Medical history, prior treatments, and baseline characteristics
| Parameter . | . |
|---|---|
| Age | 69 y |
| Sex | Male |
| BMI | 22 kg/m2 |
| Medical history | HBV Ab positive, HBV sAg negative (indicating cleared prior infection), first detected in 1980 |
| Non-A/B hepatitis since 1983, confirmed as HCV in 2003 | |
| HCV genotype 1a, RNA PCR load: 1.34E + 006 IU/mL | |
| Minimal fibrosis: Fibroscan F0/F1 5.7 KPa obtained late 2015 as workup before DAA treatment for HCV eradication | |
| Prior treatments | DAA treatment in early 2016, total course 3 months, as follows:Dasabuvir 250 mg twice dailyRibavirin 600 mg twice dailyOmbitasvir/paritaprevir/ritonavir as 12.5/75/50 mg once daily |
| Family history | Diverse malignancies |
| Alcohol consumption | 0–2 units per wk |
| Other risk factors for HCC | No diabetes |
| No known NAFLD risk factors | |
| No evidence of significant fibrosis/cirrhosis or steatosis at screening or before treatment | |
| Screening Fibroscan score | 4.3 KPa (inclusion criterion, ≤9) |
| Steatosis grade (CAP) | 186 dB |
| Parameter . | . |
|---|---|
| Age | 69 y |
| Sex | Male |
| BMI | 22 kg/m2 |
| Medical history | HBV Ab positive, HBV sAg negative (indicating cleared prior infection), first detected in 1980 |
| Non-A/B hepatitis since 1983, confirmed as HCV in 2003 | |
| HCV genotype 1a, RNA PCR load: 1.34E + 006 IU/mL | |
| Minimal fibrosis: Fibroscan F0/F1 5.7 KPa obtained late 2015 as workup before DAA treatment for HCV eradication | |
| Prior treatments | DAA treatment in early 2016, total course 3 months, as follows:Dasabuvir 250 mg twice dailyRibavirin 600 mg twice dailyOmbitasvir/paritaprevir/ritonavir as 12.5/75/50 mg once daily |
| Family history | Diverse malignancies |
| Alcohol consumption | 0–2 units per wk |
| Other risk factors for HCC | No diabetes |
| No known NAFLD risk factors | |
| No evidence of significant fibrosis/cirrhosis or steatosis at screening or before treatment | |
| Screening Fibroscan score | 4.3 KPa (inclusion criterion, ≤9) |
| Steatosis grade (CAP) | 186 dB |
Ab, antibody; BMI, body mass index; CAP, controlled attenuation parameter; DAA, direct-acting antiviral; IU, international units; NAFLD, nonalcoholic fatty liver disease; PCR, polymerase chain reaction; sAg, surface antigen.